> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbott's Third-Quarter Sales Rose 14.5%, But Reported Earnings Per Share Fell To $0.53 From $0.94
- URL: https://www.bullished.co/abbotts-third-quarter-sales-rose-14-5-but-reported-earnings-per-share-fell-to-0-53-from-0-1f51fad6/
- Published: 2026-10-21T11:51:05.000Z
- Updated: 2026-10-28T19:14:16.000Z
- Description: Adjusted earnings rose to $1.42 a share as Exact Sciences lifted sales, while amortization, interest and settlements cut reported profit.
- Author: Matteo Parrino
- Tags: Earnings, ABT, Industry: Healthcare

[Abbott](https://www.bullished.co/tag/abt/)'s third-quarter sales [rose 14.5%](https://www.prnewswire.com/news-releases/abbott-reports-third-quarter-2026-results-and-reaffirms-full-year-eps-guidance-302915370.html?ref=bullished.co) to [$13,013 million](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026066601/abt-2026q3xexhibitx991.htm?ref=bullished.co), but earnings under standard accounting fell to $0.53 a share from $0.94 a year earlier, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) and news release filed Wednesday. Adjusted earnings went the other way, rising to $1.42 from $1.30, and the gap between the two is the story.

## The finding: sales up, reported profit down

On a comparable basis, which counts Exact Sciences in both years and strips out currency, [sales grew 7.0%](https://www.prnewswire.com/news-releases/abbott-reports-third-quarter-2026-results-and-reaffirms-full-year-eps-guidance-302915370.html?ref=bullished.co). Abbott bought Exact Sciences, a cancer diagnostics company, on March 23, 2026, so the reported 14.5% includes a business that was not in the prior-year quarter.

Net earnings were $920 million versus $1,644 million a year earlier, down 44.1%. Operating earnings fell 34.0% to $1,358 million from $2,057 million.

Cancer Diagnostics, the former Exact Sciences business, brought in $968 million of sales and grew 13.8% comparably, led by Cologuard. Medical Devices grew 7.8% comparably, with double-digit growth in Electrophysiology and Rhythm Management. Nutrition grew 4.9% comparably and Established Pharmaceuticals 8.4%.

Chairman and CEO Robert B. Ford said Abbott "delivered strong third-quarter results, reflecting balanced growth across our portfolio."

## The catch: what sits between $0.53 and $1.42

Abbott's adjusted figure excludes $1.557 billion of after-tax charges, or $0.89 a share. Amortization of intangible assets was $841 million, double the $420 million of a year earlier.

The specified items also include legal settlements of about $670 million, tied to the Gill case and necrotizing enterocolitis (NEC) claims for roughly 2,000 additional infants. Other net expenses of $178 million cover acquisitions, restructuring and other items.

Below the operating line, net interest expense was $297 million versus $44 million. Selling, general and administrative costs rose 39.8% to $4,266 million, against 14.5% sales growth.

For the first nine months, reported earnings were $1.67 a share versus $2.70, while adjusted earnings were $3.88 versus $3.65.

## Guidance and what comes next

Abbott expects full-year comparable sales growth of about 6.0%. It tightened its 2026 adjusted earnings range to $5.50 to $5.55 a share, reaffirming the midpoint of the prior range. For the fourth quarter it guided to $1.62 to $1.67 adjusted. It gave no standard-accounting forecast, saying it cannot predict items such as restructuring, acquisition costs and currency.

The company declared a quarterly dividend of $0.63 a share, payable Nov. 16 to holders of record on Oct. 15\. Yahoo Finance [reports](https://finance.yahoo.com/healthcare/articles/abbott-abt-libre-keep-growing-163134597.html?ref=bullished.co) a U.S. launch of Libre Duo 10 Day is planned later in 2026.

The fourth-quarter adjusted range of $1.62 to $1.67 a share is the next number Abbott has put its name to.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ABBOTT LABORATORIES (ABT)](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026066601/abt-20261021.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit abt-2026q3xexhibitx991.htm — ABBOTT LABORATORIES 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026066601/abt-2026q3xexhibitx991.htm?ref=bullished.co) — SEC EDGAR
- [Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?](https://finance.yahoo.com/healthcare/articles/abbott-abt-libre-keep-growing-163134597.html?ref=bullished.co) — Yahoo Finance
- [Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test](https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-secures-europe-190949465.html?ref=bullished.co) — Yahoo Finance
- [Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance](https://www.prnewswire.com/news-releases/abbott-reports-third-quarter-2026-results-and-reaffirms-full-year-eps-guidance-302915370.html?ref=bullished.co) — prnewswire.com

### More on Abbott Laboratories

- [Abbott CEO Says Barron's 'Got It Totally Wrong' On Nutrition Spinoff, Calls It A Move From Strength](https://www.bullished.co/abbott-ceo-says-barrons-got-it-totally-wrong-on-nutrition-spinoff-calls-it-a-move-from-d9ea317d/)
- [Abbott Plans To Spin Off $8.5 Billion Nutrition Business By End Of 2027](https://www.bullished.co/abbott-plans-to-spin-off-8-5-billion-nutrition-business-by-end-of-2027-5afeb40c/)

[All Abbott Laboratories (ABT) coverage →](https://www.bullished.co/tag/abt/)